Mohamedtaki Tejani, MD, FACS

Mohamedtaki Tejani , MD, FACS

Medical Director - Gastrointestinal (GI) Oncology Program

Cancer

Tejani

Overview

Mohamedtaki A. Tejani, MD, received his Bachelor of Arts degree, Magna Cum Laude, from Amherst College. He later earned his medical degree from Dartmouth Medical School. Dr. Tejani went on to complete his residency at Yale-New Haven Hospital in New Haven, CT, achieving the rank of Chief Resident. Following this, he completed his fellowship training in hematology/oncology at Fox Chase Cancer Center/Temple University in Philadelphia. An award-winning physician, Dr. Tejani has authored numerous oncology-related publications. His research experience and areas of interest include gastrointestinal cancers, biomarkers and therapeutics, patient-provider communication and the culture of medicine. Dr. Tejani firmly believes that patient care is a privilege. Listening and responding to a patient’s unique story is critical in helping that family on their cancer journey. Originally from Tanzania (East Africa), he is fluent in Swahili, Hindi, Urdu and Gujarati.

Articles

A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer

FUTURE ONCOLOGY

2024

Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma

The oncologist

2024

Zanidatamab (zani) in previously treated HER2+biliary tract cancer (BTC): Impact on patient-reported pain outcomes in the phase 2b HERIZON-BTC-01 study

JOURNAL OF CLINICAL ONCOLOGY

2024

Real-world clinical effectiveness of sorafenib among patients with unresectable hepatocellular carcinoma at two centers in the United States

WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY

2023

Quality of life (QoL) outcomes in patients (pts) with zanidatamab (zani)-treated HER2-positive (HER2+) biliary tract cancer (BTC) in the phase IIb HERIZON-BTC-01 study

ANNALS OF ONCOLOGY

2023

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

LANCET ONCOLOGY

2023

Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma

The oncologist

2022

A phase II (ph2), randomized study of magrolimab with bevacizumab and FOLFIRI in previously treated patients with advanced inoperable metastatic colorectal cancer (mCRC)

ANNALS OF ONCOLOGY

2022

Feasibility of using tumor-informed circulating tumor DNA (ctDNA)-based testing for patients with anal squamous cell carcinoma

ANNALS OF ONCOLOGY

2022

Associations of Uncertainty With Psychological Health and Quality of Life in Older Adults With Advanced Cancer

JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

2021

More Publication Information

Education & Training

Education

University of Rochester School of Medicine, Rochester, NY

Residency

Yale-New Haven Medical Center, New Haven, CT

Fellowship

Fox Chase Cancer Center/Temple University, Philadelphia, PA

Associated Clinical Trials

NCT05111626

A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Cancer With FGFR2b Overexpression

This study is currently enrolling.

You are being asked to take part in Part 2 of this study because you have advanced gastric cancer (a disease in which cancer cells form in the lining of the stomach) or gastroesophageal junction cancer (a type of cancer forming ...

NCT05506943

A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen

This study is currently enrolling.

NCT04793958

A Randomized PHase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

This study is currently enrolling.

This is a study involving an investigational (experimental) drug called MRTX849, being developed by Mirati Therapeutics, Inc., which is the company that provides MRTX849 study drug and is funding and organizing the study. Inves ...

NCT04444921

A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients

This study is currently enrolling.

This study is being done to answer the following question: Will adding an immune checkpoint inhibitor to the usual combination of chemotherapy drugs help prevent your cancer from getting worse? We are doing this study because w ...

NCT05865535

AV-380-22-102: A Phase 1 Dose Escalation Study of AV-380 in Combination with Standard of Care Chemotherapy in Metastatic Cancer Patients with Cachexia and Elevated GDF-15 Levels

This study is currently enrolling.

The study involves research. The purpose of the study is to see if a single dose and multiple doses of the study drug, AV 380, are safe and tolerated in cancer participants. This study will also help to look at how AV 380 behav ...

NCT05610163

THE JANUS RECTAL CANCER TRIAL: A RANDOMIZED PHASE II TRIAL TESTING THE EFFICACY OF TRIPLET VERSUS DOUBLET CHEMOTHERAPY TO ACHIEVE CLINICAL COMPLETE RESPONSE IN
PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER

This study is currently enrolling.

To evaluate and compare the cCR rates in patients with locally advanced rectal cancer treated with neoadjuvant LCRT followed by neoadjuvant mFOLFIRINOX versus neoadjuvant LCRT followed by neoadjuvant mFOLFOX6.To evaluate and co ...

NCT04935359

A randomized, three-arm, double-blind, placebo-controlled, phase III study, comparing NIS793 with or without spartalizumab in combination with gemcitabine and nab-paclitaxel versus matching placebos combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)

The purpose of this study is to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-line mPDAC. This study aims to explore whether blo ...

NCT02912559

A021502 Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

The purpose of this study is to compare any good and bad effects of using the drug atezolizumab along with the usual chemotherapy compared to the usual chemotherapy alone. The addition of atezolizumab to the usual chemotherapy ...

NCT04137107

Duloxetine to Prevent Oxaliplatin-induced Chemotherapy-induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

This study is being because we want to find out if duloxetine can prevent oxaliplatin-induced peripheral neuropathy (also called OIPN).

NCT03377491

PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma

The purpose of this study is to evaluate the efficacy and safety of TTFields together with standard chemotherapy (gemcitabine and nab-paclitaxel) compared to standard chemotherapy (gemcitabine and nab-paclitaxel) without TTFiel ...